Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE: To quantify levels of subvisible particles and protein aggregates in repackaged bevacizumab obtained from compounding pharmacies, as well as in samples of bevacizumab and ranibizumab tested in controlled laboratory experiments. METHODS: Repackaged bevacizumab was purchased from four external compounding pharmacies. For controlled laboratory studies, bevacizumab and placebo were drawn into plastic syringes and incubated at -20°C, 4°C, and room temperature (with and without exposure to light) for 12 weeks. In addition, mechanical shock occurring during shipping was mimicked with syringes containing bevacizumab. Particle counts and size distributions were quantified by particle characterization technology. Levels of monomer and soluble aggregates of bevacizumab were determined with size-exclusion high-performance liquid chromatography (SE-HPLC). RESULTS: Repackaged bevacizumab from the compounding pharmacies had a wide range of particle counts (89,006 ± 56,406 to 602,062 ± 18,349/mL). Bevacizumab sampled directly from the original glass vial had particle counts of 63,839 ± 349/mL. There was up to a 10% monomer loss in the repackaged bevacizumab. Laboratory samples of repackaged bevacizumab and placebo had initial particle counts, respectively, of 283,675 ± 60,494/mL and 492,314 ± 389,361/mL. Freeze-thawing of both bevacizumab and placebo samples led to >1.2 million particles/mL. In all repackaged samples, most of the particles were due to silicone oil. SE-HPLC showed no significant differences for repackaged samples incubated in the laboratory under various conditions, compared with bevacizumab directly from vial. However, repeated freeze-thawing caused a more than 10% monomer loss. CONCLUSIONS: Bevacizumab repackaged in plastic syringes could contain protein aggregates and is contaminated by silicone oil microdroplets. Freeze-thawing or other mishandling can further increase levels of particle contaminants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Exposure to light has been shown to increase particulate count by 2.5 times [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protein aggregates can form under a variety of circumstances prior to intravitreal injection of the drug and they can be further induced by SO release from syringes [57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various factors can contribute to SO release from the inner cylinder wall, protein denaturing, or both [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Freeze-thawing that may occur during shipping has been demonstrated to significantly increase SO microdroplet release in bevacizumab solution, along with increased protein particle levels [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Many processes involved in the shipping, handling and storage of anti-VEGF medications and syringes can contribute to SO release and protein aggregation [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution
Thirumangalathu, R., Krishnan, S., Ricci, M. S., Brems, D. N., Randolph, T. W., & Carpenter, J. F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21719 · Cited by 294
Self-citationSustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
Good, T. J., Kimura, A. E., Mandava, N., & Kahook, M. Y. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.180729 · Cited by 245
Self-citationSilicone oil induced glaucoma: A review
Ichhpujani, P., Jindal, A., & Jay Katz, L. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1155-x · Cited by 204
Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions
Ludwig, D. B., Carpenter, J. F., Hamel, J., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21982 · Cited by 137
Self-citationHIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
Kahook, M. Y., Liu, L., Ruzycki, P. A., Mandava, N., Carpenter, J. F., Petrash, J. M., & Ammar, D. A. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cea · Cited by 130
Self-citationPersisent ocular hypertension following intravitreal ranibizumab
Bakri, S. J., McCannel, C. A., Edwards, A. O., & Moshfeghi, D. M. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0819-2 · Cited by 129
Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections
Kahook, M. Y., KIMURA, A. E., Wong, L. J., Ammar, D. A., Maycotte, M. A., & Mandava, N. (2009) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20090430-12 · Cited by 127
Self-citationSubramanian, M. L., Abedi, G., Ness, S. D., Ahmed, E., Fenberg, M. J., Daly, M. K., Houranieh, A. M., & Feinberg, E. B. (2010) · Eye · doi:10.1038/eye.2010.147 · Cited by 105
Research works printed but not linked: 2
- [15]15. Sharma DK Oma P, Krishnan S. Silicone microdroplets in protein formulations detection and enumeration. Pharm Technol 2009;33: 74-79.
- [18]18. Crampton S, Ricci M. Development and Application of a Fourier Transform Infrared (FTIR) Spectroscopy Method to Quantify Silicone Oil Extracted from Syringes. AAPS National BioTechnology. Conference. San Francisco: The American Association of Pharmaceutical Scientists; 2010.
Cited by
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Issues arise because bevacizumab has not been formulated for ocular use (Liu et al., 2011a; Ng et al., 2012; Palmer et al., 2013).”
Protein Aggregation and Particle Formation in Prefilled Glass Syringes
Gerhardt, A., Mcgraw, N. R., Schwartz, D. K., Bee, J. S., Carpenter, J. F., & Randolph, T. W. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23973 · Cited by 197
Self-citationDwivedi, M., Blech, M., Presser, I., & Garidel, P. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.008 · Cited by 188
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187
“As silicone oil forms a hydrophobic surface at the glass barrel-toliquid interface, protein degradation and aggregation might happen, as described in the literature [26,37,36,32,51].”
BackgroundAnderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Metadata
- Authors
- Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F.
- Affiliations
- University of Colorado Denver (US)
- University of Colorado Anschutz (US)
- From the Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-02-22
- Volume
- 52
- Issue
- 2
- Pages
- 1023
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC3053093
- OpenAlex
- W2031531075
- Cited by
- 199
- References
- 21
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 10 · 2021: 25 · 2020: 16 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 10 · 2015: 10 · 2014: 15 · 2013: 14 · 2012: 19
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (R01EB006006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- bevacizumab, ranibizumab, compounding pharmacies, protein aggregates, subvisible particles, freeze-thaw cycles, drug storage conditions, plastic syringes
- MeSH terms
- Bevacizumab, Ranibizumab, Antibodies, Monoclonal, Drug Compounding, Drug Packaging, Drug Stability, Drug Storage, Particle Size, Silicone Oils, Angiogenesis Inhibitors, Particulate Matter, Protein Multimerization, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.